TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06052332

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Short course radiotherapy
Description: Patients will receive 5 daily fractions of radiotherapy. Each fraction will consist of 5 Gy for a total dose of 25 Gy.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adjuvant chemotherapy (optional)
Description: The choice of the adjuvant chemotherapy is to the investigator's discretion.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Total mesorectal excision
Description: Surgery must be performed according to the principles of total mesorectal excision. A watch \& wait approach is allowed for those subjects who have clinical complete response according to the local assessment.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Total mesorectal excision
Description: Surgery must be performed according to the principles of total mesorectal excision. A watch \& wait approach is allowed for those subjects who have clinical complete response according to the local assessment.

Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: Total neoadjuvant therapy
Description: The choice of the TNT is left to the investigator's discretion.~If RAPIDO:~* SCRT (5 fractions of 5 Gy), followed by~* Up to 18 weeks of oxaliplatin based chemotherapy (mFOLFOX6 or CAPOX)~If RAPIDO light:~* SCRT (5 fractions of 5 Gy), followed by~* Up to 12 weeks of oxaliplatin based chemotherapy (mFOLFOX6 or CAPOX)~If OPRA with induction chemotherapy:~* Up to 16 weeks of oxaliplatin-based chemotherapy (mFOLFOX6 or CAPOX), followed by~* CRT (25-28 fractions of 1.8-2.0 Gy each +/- a boost to the primary tumour and involved lymph nodes, for a total of 50-56 Gy of radiation combined with either continuous infusion ﬂuorouracil or capecitabine)~If OPRA with consolidation chemotherapy:~* CRT (25-28 fractions of 1.8-2.0 Gy each +/- a boost to the primary tumour and involved lymph nodes, for a total of 50-56 Gy of radiation combined with either continuous infusion ﬂuorouracil or capecitabine) followed by~* Up to 16 weeks of oxaliplatin-based chemotherapy (mFOLFOX6 or CAPOX)
Study: NCT05819710

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zopiclone
Description: Single-dose of 7.5 mg of zopiclone

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Single-dose of placebo
Study: NCT06053606

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: cryoablation of atrial fibrillation using only 28 mm size balloon
Description: all applications in all PVs are done with 28 mm balloon

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: cryoablation of atrial fibrillation using expandable balloon (28 / 31 mm)
Description: first applications in LSPV and RSPV are done with 31 mm balloon
Study: NCT05950867

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: ECG + echocardiography
Description: Electrocardiogram and echocardiography

Intervention type: OTHER
Group type: OTHER
Intervention: Answering questionnaires
Description: Answering questionnaires about polyneuropathy symptoms (NTSS -6, COMPASS31, NIS, mPND) and also cardialogical symptoms (KCCQ-12).
Study: NCT06125925

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Radiofrequency catheter ablation (RFCA)
Description: Radiofrequency ablation is adopted in the study, instead of cryo ablation, surgical ablation or pulsed field ablation. 3-dimensional model is constructed after transseptal puncture. Circumferential pulmonary vein isolation (CPVI) is performed with irrigated contact force catheter. Previously published STABLE-SR approach is recommended as the ablation strategy beyond CPVI.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Medical Therapy
Description: AADs should be prescribed according to the current guidelines, such as amiodarone, dronedarone, or propafenone. In brief, rhythm control is preferred, including electric cardioversion. However, rate control should be considered if rhythm control is contraindicated, intolerated or unpreferred by patients.
Study: NCT06389357

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: training and counselling
Description: It includes 4 modules that develop children's communication, coping and social life skills and psychosocial preparation for the return to school process. The modules include theoretical explanations, stories, workshops and counselling sessions.
Study: NCT06445244

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Alpha-ketoglutarate supplied as 1000mg capsule
Description: AKG Double Wood® + lifestyle modification AKG Double Wood®: 500mg, qd, for one months. Lifestyle modification: intake 1400-1600 kcal/day: 54% carbohydrates, 24% proteins, 22% lipids, 108 mg cholesterol, 35 g fiber; avoid smoking and alcohol consumption; performing aerobic activity 4 days per week such as 45 min on a stationary bicycle.
Study: NCT05160168

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: THE-630
Description: Oral THE-630 administered once daily in a continuous regimen

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: THE-630
Description: Oral THE-630 administered once daily in a continuous regimen

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: THE-630
Description: Oral THE-630 administered once daily in a continuous regimen

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: THE-630
Description: Oral THE-630 administered once daily in a continuous regimen
Study: NCT05769855

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HR18034
Description: HR18034 380mg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ropivacaine HCl
Description: ropivacaine HCl 75mg.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Sodium Chloride Physiological Solution
Description: Sodium Chloride Physiological Solution 20ml
Study: NCT06058429

Intervention type: OTHER
Intervention: no intervention
Description: This is an observation study after vaccination, no intervention will be used

Intervention type: OTHER
Intervention: no intervention
Description: This is an observation study after vaccination, no intervention will be used
Study: NCT05231928

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Argon Laser Iridoplasty
Description: Argon Laser is applied to the anterior iris surface at sites and with parameters tailored according to iris configuration, pupil size, iris colour.~The device used is Nidek Argon Laser device with YAG capsulotomy or Abraham Iridotomy lens as auxilliary lenses.~-Topical Pilocarpine 2% and ocular surface anesthetic are applied prior to the procedure and Brimonidine 0.2% bid is used fo a week after the procedure together with topical dexamethasone ophthalmic solution.
Study: NCT05431972

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cardea SOLO
Description: Neurologist cardiac rhythm translation with 12 lead EKG versus Cardea SOLO
Study: NCT06445244

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Behavioral: Lifestyle modification
Description: Lifestyle modification: intake 1400-1600 kcal/day: 54% carbohydrates, 24% proteins, 22% lipids, 108 mg cholesterol, 35 g fiber; avoid smoking and alcohol consumption; performing aerobic activity 4 days per week such as 45 min on a stationary bicycle.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavioral: Lifestyle modification
Description: Lifestyle modification: intake 1400-1600 kcal/day: 54% carbohydrates, 24% proteins, 22% lipids, 108 mg cholesterol, 35 g fiber; avoid smoking and alcohol consumption; performing aerobic activity 4 days per week such as 45 min on a stationary bicycle.
Study: NCT05473416

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: McKenzie back extension exercise
Description: McKenzie's back extension exercise consists; start with your belly facing down on the mat. Angle your legs in line with your hips, point your toes, and breathe into the next movement. Gently bending your elbows, push yourself up off the floor, until you feel the extension in your back. Be mindful not to lock your elbows as you support your weight with your hands and wrists for 10 seconds. Take deep inhales and exhales as you move in and out of the pose. Patients will be performed these activities under the supervision of physiotherapist.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pilates pelvic tilt exercise
Description: Pilates pelvic tilt exercise consists; lie with your back on the floor in a neutral position with your legs bent and toes facing forward. Pull your belly button in toward your spine, pushing your pelvis up toward the ceiling. Tighten your gluteus and hip muscles as you tilt your pelvis forward. Hold for 10 seconds.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Baseline treatment
Description: Postural guidelines + proper lifting technique + stretch break Rest

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Baseline treatment
Description: Postural guidelines + proper lifting technique + stretch break Rest
Study: NCT05070559

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Active Release Technique
Description: Patients in this group will receive Active Release Technique along with conventional therapy. ART will be given with patient seated, elbow flexed and resting on the treatment table, forearm in midprone \& wrist in neutral position and then the therapist will work on the common extensor tendon by applying pressure to the tendon distal to their attachment at the elbow. The patient will start with the elbow bent and wrist straight. As the therapist hold the muscles, the patient will extend the elbow and pronate and flex the wrist while the therapist move the pressure proximally, attempting to release adhesions around and between muscle planes. Total of 15 repetitions for of 10 minutes.~CONVENTIONAL THERAPY:~* Hot pack for 15 minutes~* TENS for 15 minutes~* Ultrasound (pulsed mode, 1MHz at 1.5 W/cm2 for 5 minutes)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Graston Technique Group
Description: Patients in this group will receive IASTM along with conventional therapy. In graston technique proper application of GT3 which include application of a cream to the common extensor tendon. The GT3will be then used to common extensor tendon. In areas of increased tissue restriction, more required pressure with GT3 is applied using increased force and shorter strokes over the areas of restriction. Ice will be offered as needed for pain management after each session.~The study includes interventional protocol of 4 weeks. The sessions will be given 3 times a week for 4 weeks.~CONVENTIONAL THERAPY:~* Hot pack for 15 minutes~* TENS for 15 minutes~* Ultrasound (pulsed mode, 1MHz at 1.5 W/cm2 for 5 minutes)
Study: NCT05431972

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: 12 Lead EKG
Description: Neurologist cardiac rhythm translation with 12 lead EKG versus Cardea SOLO
Study: NCT06536140

Intervention type: OTHER
Intervention: Home observations and interview
Description: If persons want to participate, the person will be invited one week before the first observation for a 'warm-up' phone call (W1) as a preparation for the three observations and follow-up interview.~During the observations, SH will be an active participant, offering to help with activities of daily life with the person, so opportunities are created to observe and ask questions (sensory ethnography). The person will be asked to take pictures or make drawings of important things in the house as the observer will be able to better understand how they feel about exercise and PA (visual ethnography). Six weeks after the last observation (W10), formal follow-up interviews (30-60 min) with questions based on the observations that took place, will be held to explore specific issues in-depth.
Study: NCT06217211

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Remolacha
Description: BJ or PL will be administered 3 h before the start of the NO2- evaluation test since the peak in blood occurs 2-3 h after ingesting NO3-. Both drinks (BJ and PL) will be provided in an unlabeled 140ml maroon red plastic bottle. Participants will receive a randomly assigned bottle. containing 140 ml (\~ 12.8 mmol, \~ 808 mg NO3-) of BJ Beet-It-Pro Elite Shot concentrate (Beet IT; James White Drinks Ltd., Ipswich, United Kingdom) or PL.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Remolacha
Description: BJ or PL will be administered 3 h before the start of the NO2- evaluation test since the peak in blood occurs 2-3 h after ingesting NO3-. Both drinks (BJ and PL) will be provided in an unlabeled 140ml maroon red plastic bottle. Participants will receive a randomly assigned bottle. containing 140 ml (\~ 12.8 mmol, \~ 808 mg NO3-) of BJ Beet-It-Pro Elite Shot concentrate (Beet IT; James White Drinks Ltd., Ipswich, United Kingdom) or PL.
Study: NCT06359548

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Peeled ILM Reposition
Description: The ILM was stained using 0.1 mL of indocyanine green（ICG) for approximately 1minute after PPV. The ILM was grasped with end gripping forceps (Grieshaber Maxgrip 723.13; Alcon Laboratories Inc) at a point away from the center of MH around one disc diameter in inferior quadrant of macular area. First, a horizontal ILM strip was peeled off with a width approximately 1.5 to 2.5 disc diameter. Then, the edge of the horizontal ILM strip was grasped and peeled from inferior to superior area continuously.Then the ILM roll was flattened back to peeled area assisted with approximately 1.0 mL of PFO (Perfluoron, Alcon Laboratories, Inc). The position of the fixed ILM flap was adjusted under PFO bubble using flute needle or forceps if required.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: ILM Peeling
Description: The ILM was stained using 0.1 mL of indocyanine green（ICG) for approximately 1minute after PPV. The ILM was grasped with end gripping forceps (Grieshaber Maxgrip 723.13; Alcon Laboratories Inc). The strand of ILM was peeled off radially from the foveal center to the vascular arcade. As a result, a round-shaped, 2.5-disk diameter to 3.5-disk diameter ILM-peeled area was created.
Study: NCT06285422

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SC262
Description: SC262 is an allogeneic CAR -T cell therapy
Study: NCT06381739

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ChAd-triCoV/Mac
Description: Clinical-grade, fully certified ChAd-triCoV/Mac produced according to current Good Manufacturing Principles (cGMP) will be provided. A single dose of ChAd-triCoV/Mac diluted in 0.5mL formulated buffer will be aerosolized and inhaled via a mouthpiece and tidal breathing over approximately 2 minutes using the AeroNeb Solo Mesh Nebulizer.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Control
Description: A single dose of placebo (0.5mL formulated buffer) will be aerosolized and inhaled as the intervention vaccine.
Study: NCT06515457

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Eye Empower
Description: Participants will take three capsules of the Eye Empower supplement daily for three weeks.
Study: NCT06447389

Intervention type: OTHER
Group type: OTHER
Intervention: retraction cordu (SURE-CORD®PLUS)
Description: The evaluation of the effectiveness of retraction cords in determining the restoration margin in the fabrication of short fixed partial dentures for patients with missing teeth.
Study: NCT05089461

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mitoxantrone Hydrochloride Liposome
Description: Mitoxantrone Hydrochloride Liposome, intravenous injection (IV), 20 mg/m\^2. Solid tumors: every 3 weeks (q3w, 1 cycle), Lymphoma: every 4 weeks (q4w, 1 cycle).
Study: NCT05587699

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CKD-843 A 45mg(Multiple dose)
Description: 1 Injection/3 Month, 3 times Injections

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CKD-843 A 45mg
Description: Single Injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CKD-843 A 55mg(Multiple dose)
Description: 1 Injection/3 Month, 3 times Injections

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CKD-843 A 55mg
Description: Single Injection

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: CKD-843-R
Description: 0.5mg/day, 9 Month
Study: NCT05459701

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dapagliflozin 10mg Tab
Description: Dapagliflozin 10 mg once daily for 24 weeks.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT05461235

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: 2mg/kg or 200mg,iv,q3w

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: 3mg/kg or 240mg,iv,q2w

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sintilimab
Description: 200mg,iv,q3w

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Toripalimab
Description: 3mg/kg or 240mg,iv,q2w

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Camrelizumab
Description: 200mg,iv,q2w or q3w;3mg/kg,iv,q3w

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tislelizumab
Description: 200mg,iv,q3w

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: NK-Cell or DC-Cell
Description: 50ml of peripheral blood was collected 1 day before the dosing cycle for in vitro isolation and amplification of DC and NK cells; the first transfusion of DC and NK cells (not less than 1x10\^6 cells/Kg) was completed on day 14.
Study: NCT06215391

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 3d printed mask
Description: * Concurrent, prospective, non-randomized inclusion, cross-over design. A minimum of 6 patients will be included for each group, COPD, and ALS.~* T0: Patient enrollment (informed consent signing), retrospective review of the respirator log (1 month prior), variable extraction (extracting EDF files from the respirator log and data obtained from ResScan).~* During the first week, a 3D scan of the patient's face will be conducted, and the personalized 3D-printed mask (M3D) will be manufactured.~* Once ready, the mask will be fitted, and the 1-month evaluation period will begin (T1: after 1 month of M3D use). The respirator card will be downloaded in the same manner as at T0, and a respiratory polygraphy (RP) will be scheduled.~* T2: At the end of the study month, the patient will resume using a similar MC, which is new and well-fitted. After one month of MC use, the respirator log will be reviewed, and a new RP will be conducted.
Study: NCT05461053

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LMX 4 Topical Cream
Description: The intervention group will be prescribed a course of LMX4 with application of a non-permeable dressing (Tegaderm, 3M, St Paul, MN) until time of spontaneous drainage, treatment failure, or resolve of pain. LMX4 is a topical anesthetic consisting of 4% lidocaine which is Food and Drug Administration (FDA) approved for topical use in children.
Study: NCT04915261

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Lenient Arm Restriction
Description: The study will crossover between either strict arm restriction guidelines for patients or lenient arm restrictions.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Strict Arm Restriction
Description: The study will crossover between either strict arm restriction guidelines for patients or lenient arm restrictions.
Study: NCT04854785

Intervention type: OTHER
Intervention: [18F]FEPPA PET scan
Description: One \[18F\]FEPPA PET for TSPO VT, and one MRI scan

Intervention type: OTHER
Intervention: [18F]FEPPA PET scan
Description: One \[18F\]FEPPA PET for TSPO VT, and one MRI scan

Intervention type: OTHER
Intervention: [18F]FEPPA PET scan
Description: One \[18F\]FEPPA PET for TSPO VT, and one MRI scan

Intervention type: OTHER
Intervention: [11C]SL25.1188 PET scan
Description: One \[11C\]SL25.1188 PET scan for MAO-B VT, and one MRI scan

Intervention type: OTHER
Intervention: [11C]SL25.1188 PET scan
Description: One \[11C\]SL25.1188 PET scan for MAO-B VT, and one MRI scan

Intervention type: OTHER
Intervention: [11C]SL25.1188 PET scan
Description: One \[11C\]SL25.1188 PET scan for MAO-B VT, and one MRI scan
Study: NCT05067114

Intervention type: DEVICE
Intervention: Screening, detection and referral for atrial fibrillation
Description: In-pharmacy cardiovascular risk assessment plus AliveCor KardiaMobile reading
Study: NCT06488014

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Erector spina plan block (ESP)
Description: In both groups, the relevant methods will be applied at the level of the surgical incision before the surgical incision (pre-emptive) after the patient is asleep and before the patient wakes up at the end of surgery.~The dose of local anaesthetic to be administered is the same for both groups.~Drug content to be administered\*: total 25 cc volume (13.5 ml 0.5% bupivacaine + 5 ml 2% lidocaine + 1.5 ml morphine (morphine diluted with 0.9% NaCl to 1mg/ml) + 5 ml 0.9% NaCl) (These doses are the routine doses applied in such surgeries in our clinic)~\* Local anaesthetic drug doses in regional anaesthesia: source: Kirk, P. H. I. I. L. I. I. P. P., \& Berde, C. B. (2020). Local anaesthetics. Miller's Anaesthesia. 9th ed. Philadelphia: Elsevier Inc, 878-9.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Paravertebral block
Description: In both groups, the relevant methods will be applied at the level of the surgical incision before the surgical incision (pre-emptive) after the patient is asleep and before the patient wakes up at the end of surgery.~The dose of local anaesthetic to be administered is the same for both groups.~Drug content to be administered\*: total 25 cc volume (13.5 ml 0.5% bupivacaine + 5 ml 2% lidocaine + 1.5 ml morphine (morphine diluted with 0.9% NaCl to 1mg/ml) + 5 ml 0.9% NaCl) (These doses are the routine doses applied in such surgeries in our clinic)~\* Local anaesthetic drug doses in regional anaesthesia: source: Kirk, P. H. I. I. L. I. I. P. P., \& Berde, C. B. (2020). Local anaesthetics. Miller's Anaesthesia. 9th ed. Philadelphia: Elsevier Inc, 878-9.
Study: NCT04830176

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: dentifrice
Description: use of dentifrices for brushing

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: dentifrice
Description: use of dentifrices for brushing
Study: NCT05206682

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leuprorelin
Description: Leuprorelin will be used to postpone period after vaginal repair.
Study: NCT05829512

Intervention type: OTHER
Intervention: Validity and reliability study
Description: Face-to-face questionnaire study
Study: NCT04988542

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Circadian Wellness sleep SL strip
Description: Participants in the intervention group will be asked to begin Circadian Wellness sleep SL strip nightly for 30 days. Participants will continue the supplementation for the 30 days.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Circadian Wellness sleep SL strip
Description: Participants in the intervention group will be asked to begin Circadian Wellness sleep SL strip nightly for 30 days. Participants will continue the supplementation for the 30 days.